You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor.
Johnson & Johnson's latest 13F filing revealed a portfolio of 15 biotech stocks and medtech stocks. The regulatory document provides a window into where one of the world's largest healthcare companies by market cap is placing its bets. And one of those bets stands above the rest, in my opinion.
This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia.
Continue » Here's the full list of Johnson & Johnson's holdings as of June 30, 2026: Data sources: Johnson & Johnson 13F filing, Google Finance. *Market caps as of Aug. 28, 2026. One thing that immediately jumps out when looking at J&J's portfolio is that over half of its holdings are small-cap stocks. Another three are micro-cap stocks (market cap below $100 million) or nano-cap stocks (market cap below $50 million).
Two of the exceptions -- Nanobiotix and Rapport Therapeutics -- aren't far above the small-cap threshold. The only true outliers are Legend Biotech and Protagonist Therapeutics. You might also have noticed that Johnson & Johnson doesn't have large stakes in most stocks.
Its biggest investment (roughly $300 million) is in Protagonist. However, that amount is basically pocket change for J&J, which boasts a cash stockpile of around $20.8 billion. I think that it's easy to select the best stock in Johnson & Johnson's portfolio.
Extract — continue reading at the source.
